Should I buy PTC Therapeutics, Inc. (PTCT) stock or is it too late?
No reliable analyst is bullish on this stock right now. A “reliable” analyst is a firm that, on this sector, hits more than 55% of its targets and beats its sector. None of them sees upside here — which is exactly why this stock is in no JPI selection.
Firm-by-firm track record on PTC Therapeutics, Inc.
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Baird | 100 % | +69.4 % | 6 | $66 +10% |
| Wells Fargo | 100 % | +59.7 % | 5 | $109 +82% |
| RBC Capital | 86 % | +37.3 % | 7 | $75 +25% |
| Cantor Fitzgerald | 77 % | +33.4 % | 26 | $137 +129% |
| Truist Securities | 67 % | +19.1 % | 6 | $86 +44% |
| JP Morgan | 71 % | +11.8 % | 14 | $67 +12% |
| B of A Securities | 44 % | -3.6 % | 16 | $93 +55% |
| Goldman Sachs | 33 % | -14.1 % | 6 | $50 -17% |
✅ Reasons to believe
- 86% of analysts rate it a buy (Buy consensus, 7 ratings) — a sign of market conviction.
- Median price target $104, i.e. +74% from the current price ($60).
- The most reliable firm on PTCT, Wells Fargo (100% hit rate, 5 scored calls), targets $109 (call made on August 13, 2026, maturing on August 13, 2027) (+82%) in its most recent call, and $93 (call made on November 5, 2025, maturing on November 5, 2026) (+55%) in the one coming due soonest.
⚠️ Reasons to hesitate
- The consensus is not unanimous: of 7 ratings, 1 is neutral.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- No dividend: your return depends only on price appreciation.
The analyst consensus on PTCT
Median target $104 (+74%) · 7 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in PTC Therapeutics, Inc. now?
We won't decide for you. The facts: 86% of analysts rate it a buy, median target $104 (+74%), and Wells Fargo (most reliable on PTCT, 100%) targets $109. Weigh that against valuation. This is not personalized advice.
Is it too late to invest in PTC Therapeutics, Inc.?
Not according to analysts: the median target ($104) is still +74% above the current price ($60) (most reliable on PTCT: Wells Fargo, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is PTC Therapeutics, Inc. still worth investing in?
It depends on the gap between the price ($60) and its estimated value: analysts target $104 on median (+74%), with 86% buys (most reliable on PTCT: Wells Fargo, 100%). Cross-check with their real reliability on PTCT and the cautions above. Information, not advice.
What's the main risk in buying PTCT?
The consensus is not unanimous: of 7 ratings, 1 is neutral.
→ Go deeper: the full PTC Therapeutics, Inc. profile (consensus, analyst reliability, price target, performance).